Health Canada
NOTICE
Notice to stakeholders – Implementation of ICH M13A: Bioequivalence for immediate release solid oral dosage forms
Published: 12/27/2025Detected: 3/22/2026
Summary preview
Implements ICH M13A to strengthen the bioequivalence evidence expectations for immediate release solid oral dosage forms, aligning Canadian expectations with an international framework.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from HEALTH CANADA.
More from Health Canada
- Advisory Committee: Review of the Federal Approach to Pandemic Science Advice and Research Coordination10/2/2026
- Advisory Committee: National Pharmacare Committee of Experts10/2/2026
- Advisory Committee: Ministerial Advisory Council on Mental Health10/2/2026
- Advisory Committee: Expert Task Force on Substance Use10/2/2026
- Advisory Committee: Expert Panel on MAID and Mental Illness10/2/2026